IGC Pharma (IGC) Share-based Compensation (2011 - 2025)
IGC Pharma (IGC) posted quarterly Share-based Compensation of $730000.0 for Q3 2025, up 81.59% year-over-year from $402000.0 in Q3 2024, and up 61.5% quarter-over-quarter from $452000.0 in Q2 2025.
IGC Pharma (IGC) Share-based Compensation (2011 - 2025) Analysis & Trends
IGC Pharma (IGC) has reported Share-based Compensation for 15 consecutive years, with $730000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Share-based Compensation rose 81.59% year-over-year to $730000.0; the TTM figure through Sep 2025 stood at $2.0 million (up 20.84% YoY), while the FY2026 annual figure was $1.0 million, down 38.48% from the prior year.
- Share-based Compensation grew to $730000.0 in Q3 2025 per IGC's latest filing, from $452000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.2 million in Q2 2022 and bottomed at $125000.0 in Q2 2021.
- Historically, Share-based Compensation has averaged $514210.5 across 5 years, with a median of $455000.0 in 2025.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 821.6% — and 2023, when it sank 69.01%.
- IGC Pharma's Share-based Compensation stood at $523000.0 in 2021, then decreased by 7.46% to $484000.0 in 2022, then grew by 8.68% to $526000.0 in 2023, then declined by 27.57% to $381000.0 in 2024, then jumped by 91.6% to $730000.0 in 2025.
- Business Quant data shows IGC's Share-based Compensation at $730000.0 in Q3 2025, $452000.0 in Q2 2025, and $455000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 730,000.00 |
| Sep 30, 2025 | 730,000.00 |
| Jun 30, 2025 | 452,000.00 |
| Jun 30, 2025 | 452,000.00 |
| Mar 31, 2025 | 455,000.00 |
| Mar 31, 2025 | 455,000.00 |
| Dec 31, 2024 | 381,000.00 |
| Dec 31, 2024 | 381,000.00 |
| Sep 30, 2024 | 402,000.00 |
| Sep 30, 2024 | 402,000.00 |
| Jun 30, 2024 | 402,000.00 |
| Jun 30, 2024 | 402,000.00 |
| Mar 31, 2024 | 340,000.00 |
| Mar 31, 2024 | 340,000.00 |
| Dec 31, 2023 | 526,000.00 |
| Dec 31, 2023 | 526,000.00 |
| Sep 30, 2023 | 550,000.00 |
| Sep 30, 2023 | 550,000.00 |
| Jun 30, 2023 | 357,000.00 |
| Jun 30, 2023 | 357,000.00 |